PRINCETON, N.J. & CAMBRIDGE, Mass.
Results demonstrate that treatment with Reblozyl provides significant reduction in transfusion burden for patients with beta thalassemia-associated anemia compared to placebo
PRINCETON, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced that the New England Journal of Medicine (NEJM) has published results from BELIEVE, the pivotal Phase 3 study evaluating the safety and efficacy of Reblozyl (luspatercept-aamt) for the treatment of anemia in adults with beta thalassemia who require regular red blood cell (RBC) transfusions.
Bristol Myers Squibb Media: email@example.com 609-252-3345 Rose Weldon firstname.lastname@example.org Investors: Tim Power 609-252-7509 email@example.com Acceleron Pharma Inc. Media: Matt Fearer, (617) 301-9557 Director, Corporate Communications Investors: Todd James, (617) 649-9393 Senior Vice President, Corporate Affairs and Investor Relations
Ticker: BMY Exchange: NYSE
Ticker: XLRN Exchange: NASDAQ
$BMY announces publication of Phase 3 data in @NEJM for the first FDA-approved treatment for adults with #betathalassemia https://www.bms.com/media/press-releases.html